saxagliptin + thiazolidinedione

Saxagliptin + thiazolidinedione is a combination therapy used in the treatment of type 2 diabetes mellitus in adults inadequately controlled on thiazolidinedione monotherapy. Saxagliptin is a selective, reversible dipeptidyl peptidase-4 (DPP-4) inhibitor that works by increasing levels of incretin hormones, thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner. Thiazolidinediones, such as pioglitazone or rosiglitazone, are peroxisome proliferator-activated receptor gamma (PPARγ) agonists that improve insulin sensitivity in adipose tissue, muscle, and the liver. The combination targets different aspects of glycemic regulation and provides a statistically significant improvement in HbA1c versus thiazolidinedione monotherapy, with a tolerable safety profile[3][5][6].